SWOT Analysis for Orchestra BioMed Holdings Inc

Rising Net Cash Flow and Cash from Operating activity
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Company with Low Debt
Increasing Revenue every quarter for the past 3 quarters
Stock with Low PE (PE < = 10)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter